Skip to main content

Resources

Insights for Drug Development Leaders

Emerging biopharma companies are outpacing big pharma in innovations and drug launches. These teams need clarity and a cost conscious mindset to reach the clinic. We provide strategic insights for teams navigating early drug and platform development. These tools, frameworks and concepts are derived from 25+ years of experience in infectious disease and drug development.

Dr. Rodriguez publishes weekly on LinkedIn about strategic concepts and how AI is changing early-stage product development. The insights and perspectives below are drawn from her LinkedIn posts and her experience in drug development.

Browse by Category

Strategy

5 articles

Target Product Profiles

2 articles

Investor Narratives

2 articles

Strategy

Strategy in Early Drug Development: Why Clarity is Your Most Valuable Asset

Why is strategy so difficult to explain? Ask 10 people this question, and you’ll likely get 10 different answers. Understanding what strategy is and how to build one becomes mission-critical when navigating drug development. So let’s talk about it. What is strategy?

Read
Strategy

Breaking Out of Red Oceans: Applying Value Innovation to Early Drug Development

Many innovators become trapped in “red oceans,” where biotechs fiercely compete for the same patients, price points, and treatment standards. Blue Ocean Strategy identifies and creates “blue oceans,” untapped market spaces where the industry rules are still undefined, making competition irrelevant.

Read
Strategy

Is a Robust Strategy Required to Bring a Drug Candidate into the Clinic?

Nope, not at all. Numerous companies spend millions of dollars each year developing drugs with vague aspirations and unclear product characteristics, burning time, money and resources along the way. I have seen it time and time again. Strategies mistaken for goals, plans, mission and vision statements. Vague statements of generalization that can be applied to any new drug in its competitive arena.

Read
Strategy

Value Innovate from within Competitive Drug Market Spaces.

New drug market spaces can be created in fiercely competitive therapeutic areas. Biopharma offers many examples of Blue Ocean’s value innovation (the pursuit of value and affordability) in action. IL-23 biologics are the current market leaders for moderate-to-severe plaque (M2S) psoriasis due to their efficacy (PASI90/100), speed to clearance, and therapeutic durability. Currently, all biologics (TNFα, IL-12, IL-17, and IL-23) for M2S psoriasis are administered IV or SC.

Read
Strategy

Beyond Efficacy and Safety: How Drug Innovators Can Create New Market Space

What unique value does your drug provide that separates you from your competitors? Can you state this clearly?

Read
TPP

The Power of the Target Product Profile: Find Strategic Clarity in Early Drug Development

If you don’t know where you are going, how do you get there? The same applies to drug development. If you don’t know what drug you are making, or who you are making it for, how can you build it?

Read
TPP

Prioritize Everything and Focus Disappears

Everything is important! Those 3 mouse challenge studies must start this week! Update the investor deck and program dashboard for C-level TODAY. Get it all done!

Read
Investor Narratives

A Clear Path to Revenue Reduces Investor Uncertainty in Drug Development

Founders often struggle to transform innovative discoveries into a fundable business strategy. They master the science, but rarely receive training in the commercial aspects of drug development. A drug development strategy without a clear path to revenue leaves VC firms and grant funders wondering how their investment(s) will pay off. Guide them by painting a picture of your first transaction.

Read
Investor Narratives

Four Keys to Unlock Capital for Drug and Platform Innovations

Early-stage drug and platform programs cannot reach patients without capital. To raise that capital, founders must convince investors that their team can move a product from concept to the clinic and generate a favorable safety data package in Phase I to enter pivotal-stage trials.

Read

Follow the Journey

New insights on drug development strategy published weekly on LinkedIn. Subscribe below for monthly digests delivered to your inbox.

Follow Dr. Rodriguez on LinkedIn

No spam. Unsubscribe anytime. One email per month.